Neoadjuvant Systemic Chemotherapy in Sebaceous Gland Carcinoma of the Eyelid: A Retrospective Study.
Eyelid
Neoadjuvant chemotherapy
Neoadjuvant systemic chemotherapy
Pathological complete remission
Sebaceous gland carcinoma
Journal
Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
20
10
2020
accepted:
14
03
2021
entrez:
4
10
2021
pubmed:
5
10
2021
medline:
5
10
2021
Statut:
ppublish
Résumé
There are sparse data on neoadjuvant systemic chemotherapy (NACT) in eyelid sebaceous gland carcinoma (SGC). The aim of this study was to evaluate efficacy and outcomes with NACT in eyelid SGC. We retrospectively analyzed 8 patients who received platinum-based NACT. The median number of cycles per patient was 4 (range, 3-5). The mean percentage reduction of tumor diameter after NACT was 71% (range, 30-100%). Two patients had a radiological complete response (CR). After NACT, surgical treatment for residual tumor was performed in 5 cases. One patient had a pathological CR and is recurrence free for 11 years. After a mean follow-up period of 44.5 months (range, 9-109), tumor recurrence occurred in 4 cases. Among these 4 cases, 3 were rechallenged with the same regimen and all responded. Systemic NACT has a role in eyelid SGC, downstages the tumor, and allows less aggressive and organ-sparing surgeries, warranting a prospective study.
Identifiants
pubmed: 34604196
doi: 10.1159/000515857
pii: oop-0007-0251
pmc: PMC8443954
doi:
Types de publication
Case Reports
Langues
eng
Pagination
251-256Informations de copyright
Copyright © 2021 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Hum Pathol. 2015 Oct;46(10):1437-42
pubmed: 26220160
Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):643-7
pubmed: 2777652
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):605-11
pubmed: 21300468
Ophthalmic Plast Reconstr Surg. 2016 Jan-Feb;32(1):35-9
pubmed: 25675161
N C Med J. 1985 Sep;46(9):473-4
pubmed: 3864018
Br J Ophthalmol. 2020 Jun;104(6):879-884
pubmed: 30940620
Br J Ophthalmol. 2021 Jan;105(1):48-56
pubmed: 32277010
Br J Ophthalmol. 2017 Apr;101(4):536-542
pubmed: 28119291
Ophthalmic Plast Reconstr Surg. 2000 May;16(3):211-5
pubmed: 10826762
Chin Med J (Engl). 1979 Oct;92(10):671-6
pubmed: 116808
Graefes Arch Clin Exp Ophthalmol. 2013 Oct;251(10):2479-80
pubmed: 23708701
Cancer. 2009 Jan 1;115(1):158-65
pubmed: 18988294
Ophthalmic Plast Reconstr Surg. 2005 Jul;21(4):307-9
pubmed: 16052148
Hum Pathol. 1982 Feb;13(2):113-22
pubmed: 7076199
Ocul Oncol Pathol. 2019 Apr;5(3):210-219
pubmed: 31049330
J Am Acad Dermatol. 1995 Jul;33(1):1-15; quiz 16-8
pubmed: 7601925
Surv Ophthalmol. 2005 Mar-Apr;50(2):103-22
pubmed: 15749305
Ophthalmology. 2002 Nov;109(11):2129-33
pubmed: 12414427
AMA Arch Ophthalmol. 1959 Feb;61(2):282-90
pubmed: 13616795
Ophthalmic Plast Reconstr Surg. 2010 Sep-Oct;26(5):366-8
pubmed: 20856079
Dermatol Surg. 2007 Mar;33(3):333-9
pubmed: 17338692